This Week in Cardiology

Six major trials from the ESC meeting in Paris are reviewed by John Mandrola, MD, in this week's podcast.

Digital health, a new LDL-c lowering drug, PCSK9i outcomes in higher risk patients, and an ESC preview are discussed by John Mandrola in this week's podcast.

TAVR, baroreflex activation for heart failure, dapagliflozin for HF, and myocardial viability are the topics discussed by John Mandrola in this week's podcast.

AI for AF detection, syncope and PE, thoracentesis, fish oil, and why doctors should organize are the topics covered by John Mandrola in this week's podcast.

Digoxin, acupuncture and angina, heart failure with preserved ejection fraction, bariatric surgery, and cardiac device complications are the topics John Mandrola covers in this week's podcast.

CRT in patients with non-LBBB, ezetimibe, lifestyle diseases in the young, end of life care, and diabetes for the cardiologist are the topics John Mandrola, MD discusses in this week's podcast

Deprescribing beta bockers, interrupting oral anticoagulants, sudden death, quality measures, and acute stroke care are the topics John Mandrola, MD discusses in this week's podcast.

High-sensitivity troponin assays, nursing education, negative risk markers, valve-in-valve TAVRs, and the use of AI in medical practice are covered in this week's podcast.

Medical reversals, conflict of interest in the cardiac cath lab, cardiologist burnout, and changes in TAVR rules are discussed by John Mandrola, MD, in this week's podcast.

FDA hearings on paclitaxel devices in PAD, health news spin, myocarditis, difficult conversations, and TAVR in patients with end stage renal disease (ESRD) are discussed in this week's podcast.